Jobs

ABOUT RXCELERATE


The RxCelerate group is an out-sourced drug development platform and is one of the fastest growing companies in the UK. Our client base ranges from virtual biotech companies all the way up to 3 of the top 15 global pharmaceutical giants. We design and deliver complete drug development programs and project management for our clients spanning from an idea up to and including Phase II clinical studies.

Business Development Executive - Spin-out


Salary: £50k-70k


Location: London, flexible working requests will be considered


Please note that there is no closing date for this role. Please do not delay your application to avoid disappointment.


The Commercial Partnerships team (CP) is dedicated to the development and commercialisation of innovative research. The team accelerates the translation of new ideas into treatments by bringing together the expertise, capabilities, and resources of CRUK and its academic network with that of industry partners.

Mogrify is a cell therapy development company. We have developed a systematic big data-science approach powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription factors (in vitro) or small molecules (in vivo) for direct cell programming. This allows the conversion of any mature cell type into any other mature cell type without traversing a pluripotent stem cell- or progenitor cell-state. We are applying this approach to address the issues of efficacy, safety and scalability currently associated with cell therapy development.

Cerevance is a pharmaceutical company harnessing a novel technology platform to deliver life-changing therapeutics for patients. Focused on neurological diseases, our strengths include a pipeline of novel discovery and clinical-stage compounds, as well as a proven team (for more information, see www.cerevance.com). Our UK research operation is seeking to appoint multiple Research Scientists based in our Cambridge UK facility (Cambridge Science Park).

Cerevance is a pharmaceutical company harnessing a novel technology platform to deliver life-changing therapeutics for patients. Focused on neurological diseases, our strengths include a pipeline of novel discovery and clinical-stage compounds, as well as a proven team (for more information, see www.cerevance.com). Our UK research operation is seeking to appoint multiple Research Scientists based in our Cambridge UK facility (Cambridge Science Park).

Mogrify is a cell therapy development company. We have developed a systematic big data-science approach powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription factors (in vitro) or small molecules (in vivo). This allows the conversion of any mature cell type into any other mature cell type without traversing a pluripotent stem cell- or progenitor cell-state. We are applying this approach to address the issues of efficacy, safety and scalability currently associated with cell therapy development.

Mogrify is a cell therapy development company. We have developed a systematic big data-science approach (Rackham et al., Nature Genetics, 2016) powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription factors (in vitro) or small molecules (in vivo). This allows the conversion of any mature cell type into any other mature cell type without traversing a pluripotent stem cell- or progenitor cell-state.

Mogrify is a cell therapy development company. We have developed a systematic big data-science approach (Rackham et al., Nature Genetics, 2016) powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription factors (in vitro) or small molecules (in vivo). This allows the conversion of any mature cell type into any other mature cell type without traversing a pluripotent stem cell- or progenitor cell-state.

Mogrify is a cell therapy development company whose technology was developed in order to identify the combination of transcription factors required to convert any cell type into any other cell type. We are applying this approach to address the issues of efficacy, safety and scalability currently associated with cell therapy development.

OMass Therapeutics specializes in applying state-of-the-art native mass spectrometry platforms to characterizing challenging protein assemblies, including membrane proteins. By preserving the structures of protein assemblies, we provide novel structural insights into large, dynamic complexes. The company vision is to build an integrated drug discovery company, with these technologies at its core, and deliver novel therapies to patients.

Pages